News and Announcements
DMX Raises $5m While Outperforming All Ords by 75% Since Launch
- Published July 12, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
DMX Capital Partners has raised c. $5m of its $15m target capital raise with significant interest building.
- 75% out-performance of the All Ords after all fees since launch 2 years and 3 months ago.
- Fund well positioned for continued significant out-performance through exposure to under-valued, high quality smaller companies with catalysts coming.
- Average fund price/earnings ratio of under 10x FY18 earnings.
- Provides exposure to under-owned asset class with low correlation to broader market.
ABOUT DMX ASSET MANAGEMENT
DMX Capital Partners is well positioned in high quality, largely undiscovered ASX listed smaller companies which are trading well below their intrinsic value. The portfolio companies’ profiles are expected to continue rising in the years ahead as the market gets to know them better, and DMX Capital Partners’ investors should benefit through that process. DMX Capital Partners has out-performed the All Ordinaries Index by 76.8% after fees since launch 21 months ago. The fund continues to hold meaningful levels of cash (around 25%) so as to take advantage of attractive opportunities as they become available. Past returns are not a guide of future performance.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
